GB9510757D0 - Therapeuticaly active compounds - Google Patents

Therapeuticaly active compounds

Info

Publication number
GB9510757D0
GB9510757D0 GBGB9510757.9A GB9510757A GB9510757D0 GB 9510757 D0 GB9510757 D0 GB 9510757D0 GB 9510757 A GB9510757 A GB 9510757A GB 9510757 D0 GB9510757 D0 GB 9510757D0
Authority
GB
United Kingdom
Prior art keywords
therapeuticaly
active compounds
compounds
active
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
GBGB9510757.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Wellcome Foundation Ltd
Original Assignee
Wellcome Foundation Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to GB9418852A priority Critical patent/GB9418852D0/en
Priority to GBGB9507788.9A priority patent/GB9507788D0/en
Application filed by Wellcome Foundation Ltd filed Critical Wellcome Foundation Ltd
Priority to GBGB9510757.9A priority patent/GB9510757D0/en
Publication of GB9510757D0 publication Critical patent/GB9510757D0/en
Application status is Pending legal-status Critical

Links

GBGB9510757.9A 1994-09-19 1995-05-26 Therapeuticaly active compounds Pending GB9510757D0 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
GB9418852A GB9418852D0 (en) 1994-09-19 1994-09-19 Anti-tumour compounds
GBGB9507788.9A GB9507788D0 (en) 1995-04-13 1995-04-13 Antitumour compounds
GBGB9510757.9A GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
GBGB9510757.9A GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds
EP19950931351 EP0782570A1 (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
IL11534195A IL115341D0 (en) 1994-09-19 1995-09-18 Quinoline and quinazoline derivatives their preparation and pharmaceutical compositions containing them
PCT/GB1995/002202 WO1996009294A1 (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
AU34824/95A AU3482495A (en) 1994-09-19 1995-09-18 Substituted heteroaromatic compounds and their use in medicine
JP50974095A JPH10505600A (en) 1994-09-19 1995-09-18 Their use in substituted heterocyclic compounds and agents
TR95/01137A TR199501137A2 (en) 1994-09-19 1995-09-19 therapeutically active components

Publications (1)

Publication Number Publication Date
GB9510757D0 true GB9510757D0 (en) 1995-07-19

Family

ID=27267381

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB9510757.9A Pending GB9510757D0 (en) 1994-09-19 1995-05-26 Therapeuticaly active compounds

Country Status (7)

Country Link
EP (1) EP0782570A1 (en)
JP (1) JPH10505600A (en)
AU (1) AU3482495A (en)
GB (1) GB9510757D0 (en)
IL (1) IL115341D0 (en)
TR (1) TR199501137A2 (en)
WO (1) WO1996009294A1 (en)

Families Citing this family (219)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6645969B1 (en) 1991-05-10 2003-11-11 Aventis Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit CSF-1R receptor tyrosine kinase
TW321649B (en) * 1994-11-12 1997-12-01 Zeneca Ltd
GB9424233D0 (en) * 1994-11-30 1995-01-18 Zeneca Ltd Quinazoline derivatives
GB9508565D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quiazoline derivative
GB9508537D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
GB9508538D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
EP0824525B1 (en) * 1995-04-27 2001-06-13 AstraZeneca AB Quinazoline derivatives
GB9508535D0 (en) * 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivative
GB9624482D0 (en) 1995-12-18 1997-01-15 Zeneca Phaema S A Chemical compounds
US5760041A (en) * 1996-02-05 1998-06-02 American Cyanamid Company 4-aminoquinazoline EGFR Inhibitors
SI0880508T1 (en) 1996-02-13 2003-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
GB9603095D0 (en) 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline derivatives
GB9603097D0 (en) * 1996-02-14 1996-04-10 Zeneca Ltd Quinazoline compounds
AT211134T (en) 1996-03-05 2002-01-15 4-anilinoquinazoline derivatives
AT213730T (en) 1996-04-12 2002-03-15 Warner Lambert Co kinases reversible inhibitors of tyrosine
GB9607729D0 (en) * 1996-04-13 1996-06-19 Zeneca Ltd Quinazoline derivatives
FR2750862B1 (en) * 1996-07-12 1998-10-16 Dupin Jean Pierre Using dinitrogen heterocycles fused with an aromatic or heteroaromatic system for the treatment of thromboembolic diseases
WO1998002434A1 (en) 1996-07-13 1998-01-22 Glaxo Group Limited Fused heterocyclic compounds as protein tyrosine kinase inhibitors
HRP970371A2 (en) 1996-07-13 1998-08-31 Kathryn Jane Smith Heterocyclic compounds
CA2265630A1 (en) * 1996-09-13 1998-03-19 Gerald Mcmahon Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders
US6004967A (en) * 1996-09-13 1999-12-21 Sugen, Inc. Psoriasis treatment with quinazoline compounds
CN1252054C (en) 1996-09-25 2006-04-19 曾尼卡有限公司 Qinoline derivatives inhibiting effect of growth factors
GB9718972D0 (en) 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
DE69739986D1 (en) * 1996-10-01 2010-10-21 Kyowa Hakko Kogyo Kk Nitrogen-containing heterocyclic compounds
EP0837063A1 (en) * 1996-10-17 1998-04-22 Pfizer Inc. 4-Aminoquinazoline derivatives
US6225318B1 (en) 1996-10-17 2001-05-01 Pfizer Inc 4-aminoquinazolone derivatives
ZA9802771B (en) * 1997-04-03 1999-10-01 American Cyanamid Co Substituted 3-Cyano Quinolines.
US6002008A (en) * 1997-04-03 1999-12-14 American Cyanamid Company Substituted 3-cyano quinolines
US5929080A (en) * 1997-05-06 1999-07-27 American Cyanamid Company Method of treating polycystic kidney disease
ZA9806729B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitors of tyrosine kinases
ZA9806732B (en) * 1997-07-29 1999-02-02 Warner Lambert Co Irreversible inhibitiors of tyrosine kinases
TW436485B (en) * 1997-08-01 2001-05-28 American Cyanamid Co Substituted quinazoline derivatives
US6251912B1 (en) 1997-08-01 2001-06-26 American Cyanamid Company Substituted quinazoline derivatives
US6323209B1 (en) 1997-11-06 2001-11-27 American Cyanamid Company Method of treating or inhibiting colonic polyps
GB9800575D0 (en) * 1998-01-12 1998-03-11 Glaxo Group Ltd Heterocyclic compounds
RS49779B (en) 1998-01-12 2008-06-05 Glaxo Group Limited, Byciclic heteroaromatic compounds as protein tyrosine kinase inhibitors
AT413386T (en) 1998-01-29 2008-11-15 Amgen Inc Ppar-gamma modulators
AU3053999A (en) 1998-03-31 1999-10-25 Kyowa Hakko Kogyo Co. Ltd. Nitrogenous heterocyclic compounds
US6706721B1 (en) 1998-04-29 2004-03-16 Osi Pharmaceuticals, Inc. N-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine mesylate anhydrate and monohydrate
CA2333392A1 (en) 1998-05-28 1999-12-02 Parker Hughes Institute Quinazolines for treating brain tumor
US6800649B1 (en) 1998-06-30 2004-10-05 Parker Hughes Institute Method for inhibiting c-jun expression using JAK-3 inhibitors
SK287805B6 (en) * 1998-08-18 2011-10-04 The Regents Of The University Of California Use of epidermal growth factor receptor (EGF-R) antagonist for the manufacture of a medicament for the treatment of hypersecretion of mucus in airways
US7354894B2 (en) 1998-08-18 2008-04-08 The Regents Of The University Of California Preventing airway mucus production by administration of EGF-R antagonists
AU5682799A (en) * 1998-08-21 2000-03-14 Parker Hughes Institute Quinazoline derivatives
EP1510212A1 (en) * 1998-08-21 2005-03-02 Parker Hughes Institute Use of 4-substituted-quinazoline derivatives for producing therapeutic agents
AU2012209038B2 (en) * 1998-09-29 2013-09-26 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
US6297258B1 (en) 1998-09-29 2001-10-02 American Cyanamid Company Substituted 3-cyanoquinolines
US6288082B1 (en) 1998-09-29 2001-09-11 American Cyanamid Company Substituted 3-cyanoquinolines
PL218769B1 (en) 1998-09-29 2015-01-30 Wyeth Holdings Corporation Substituted 3-cyanoquinolines as protein tyrosine kinases inhibitors
GB9824579D0 (en) 1998-11-10 1999-01-06 Novartis Ag Organic compounds
IL144461D0 (en) * 1999-01-22 2002-05-23 Kirin Brewery Quinoline and quinazoline derivatives and pharmaceutical compositions containing them
TW519541B (en) 1999-01-27 2003-02-01 Pfizer Prod Inc Substituted bicyclic derivatives useful as anticancer agents
JP3270834B2 (en) 1999-01-27 2002-04-02 ファイザー・プロダクツ・インク Useful heteroaromatic bicyclic derivatives as anticancer agents
GB9904103D0 (en) 1999-02-24 1999-04-14 Zeneca Ltd Quinoline derivatives
US6258820B1 (en) 1999-03-19 2001-07-10 Parker Hughes Institute Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines
GB9910580D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
GB9910579D0 (en) 1999-05-08 1999-07-07 Zeneca Ltd Chemical compounds
US7041691B1 (en) 1999-06-30 2006-05-09 Amgen Inc. Compounds for the modulation of PPARγ activity
US6933299B1 (en) 1999-07-09 2005-08-23 Smithkline Beecham Corporation Anilinoquinazolines as protein tyrosine kinase inhibitors
JP2003504363A (en) 1999-07-09 2003-02-04 グラクソ グループ リミテッド Anilinoquinazoline such as protein tyrosine kinase inhibitors
US6432979B1 (en) 1999-08-12 2002-08-13 American Cyanamid Company Method of treating or inhibiting colonic polyps and colorectal cancer
ES2334879T3 (en) 1999-09-21 2010-03-17 Astrazeneca Ab Quinazoline derivatives and their use as pharmaceuticals.
SK3832002A3 (en) * 1999-09-21 2002-11-06 Astrazeneca Ab Quinazoline compounds and pharmaceutical compositions containing them
PT1244647E (en) 1999-11-05 2006-10-31 Astrazeneca Ab Quinazoline derivatives as vegf inhibitors
PT1233948E (en) 1999-11-11 2009-04-16 Osi Pharm Inc Stable polymorph of n-(3-ethynylphenylamino)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride, methods of production, and pharmaceutical uses thereof
US7087613B2 (en) 1999-11-11 2006-08-08 Osi Pharmaceuticals, Inc. Treating abnormal cell growth with a stable polymorph of N-(3-ethynylphenyl)-6,7-bis(2-methoxyethoxy)-4-quinazolinamine hydrochloride
HN2000000026S1 (en) * 1999-11-30 2002-10-01 Carlos Roberts Avalos industrial model square table
US6638929B2 (en) 1999-12-29 2003-10-28 Wyeth Tricyclic protein kinase inhibitors
US6977259B2 (en) 2000-01-28 2005-12-20 Astrazeneca Ab Quinoline derivatives and their use as aurora 2 kinase inhibitors
US6593324B2 (en) 2000-03-01 2003-07-15 Orion Corporation Dervatives of quinoline as alpha-2 antagonists
FI20000480A0 (en) * 2000-03-01 2000-03-01 Orion Yhtymae Oyj Quinoline and naphthalene-2 ​​alpha antagonists
US6608048B2 (en) 2000-03-28 2003-08-19 Wyeth Holdings Tricyclic protein kinase inhibitors
US6521618B2 (en) 2000-03-28 2003-02-18 Wyeth 3-cyanoquinolines, 3-cyano-1,6-naphthyridines, and 3-cyano-1,7-naphthyridines as protein kinase inhibitors
GB0007657D0 (en) 2000-03-29 2000-05-17 Celltech Therapeutics Ltd Chemical compounds
CA2404919A1 (en) * 2000-04-06 2002-10-01 Kyowa Hakko Kogyo Co. Ltd. Diagnostic and therapeutic agents for rheumatoid arthritis
MXPA02009891A (en) 2000-04-07 2003-03-27 Astrazeneca Ab Quinazoline compounds.
US6653332B2 (en) 2000-05-03 2003-11-25 Tularik Inc. Combination therapeutic compositions and method of use
DE10023484A1 (en) * 2000-05-09 2001-11-22 Schering Ag New 2-((cycloalkyl- or heterocyclyl-alkyl)-amino)-benzamide derivatives, are VEGF receptor, KDR kinase and FLT kinase inhibitors useful e.g. for treating tumors, psoriasis, arthritis or renal or ophthalmological diseases
CN100345844C (en) 2000-06-06 2007-10-31 阿斯特拉曾尼卡有限公司 Quinazoline derivatives for the treatment of tumours
NZ524461A (en) 2000-08-18 2004-12-24 Millennium Pharm Inc Quinazoline derivatives as kinase inhibitors
WO2002016352A1 (en) 2000-08-21 2002-02-28 Astrazeneca Ab Quinazoline derivatives
DE10042059A1 (en) * 2000-08-26 2002-03-07 Boehringer Ingelheim Pharma Bicyclic heterocycles, medicaments containing these compounds, their use and processes for their preparation
IL155447D0 (en) 2000-10-20 2003-11-23 Eisai Co Ltd Nitrogenous aromatic ring compounds
USRE43098E1 (en) 2001-01-08 2012-01-10 Millennium Pharmaceuticals, Inc. Nitrogenous heterocyclic compounds and process for making nitrogenous heterocyclic compounds and intermediates thereof
DE60144284D1 (en) 2000-11-01 2011-05-05 Millennium Pharm Inc Nitrogen-containing heterocyclic compounds and methods for their preparation
EP1337513A1 (en) 2000-11-02 2003-08-27 AstraZeneca AB 4-substituted quinolines as antitumor agents
AU1071402A (en) 2000-11-02 2002-06-11 Astrazeneca Ab Substituted quinolines as antitumor agents
GB0104422D0 (en) * 2001-02-22 2001-04-11 Glaxo Group Ltd Quinoline derivative
GB0110797D0 (en) * 2001-05-02 2001-06-27 Celltech R&D Ltd Chemical compounds
US20060004437A1 (en) 2001-08-29 2006-01-05 Swaminathan Jayaraman Structurally variable stents
EP1447405A4 (en) * 2001-10-17 2005-01-12 Kirin Brewery Quinoline or quinazoline derivatives inhibiting auto-phosphorylation of fibroblast growth factor receptors
CN100343238C (en) * 2001-11-03 2007-10-17 阿斯特拉曾尼卡有限公司 Quinazoline derivatives as antitumor agents
GB0126433D0 (en) * 2001-11-03 2002-01-02 Astrazeneca Ab Compounds
UA75482C2 (en) * 2001-12-12 2004-09-15 Pfizer Prod Inc Salts of e-2-methoxy-n-(3-{4-[3-methyl-4-(6-methylpyridine-3-yloxy)phenylamino]quinozaline -6-yl}alyl)acetamide, a method for the preparation and use thereof for the treatment of cancer
WO2003055491A1 (en) 2001-12-24 2003-07-10 Astrazeneca Ab Substituted quinazoline derivatives as inhibitors of aurora kinases
TW200406390A (en) 2002-01-17 2004-05-01 Neurogen Corp Substituted quinazolin-4-ylamine analogues
WO2003066602A1 (en) 2002-02-06 2003-08-14 Ube Industries, Ltd. Process for producing 4-aminoquinazoline compound
EP1528925B1 (en) 2002-07-09 2009-04-22 Astrazeneca AB Quinazoline derivatives for use in the treatment of cancer
GB0215823D0 (en) 2002-07-09 2002-08-14 Astrazeneca Ab Quinazoline derivatives
EP1521747B1 (en) 2002-07-15 2018-09-05 Symphony Evolution, Inc. Receptor-type kinase modulators and methods of use
US7615565B2 (en) 2002-07-31 2009-11-10 Bayer Schering Pharma Aktiengesellschaft VEGFR-2 and VEGFR-3 inhibitory anthranilamide pyridines
WO2004011456A1 (en) 2002-07-31 2004-02-05 Danter Wayne R Protein tyrosine kinase inhibitors
WO2004033446A1 (en) 2002-10-09 2004-04-22 Danter Wayne R Protein tyrosine kinase inhibitors
GB0225579D0 (en) 2002-11-02 2002-12-11 Astrazeneca Ab Chemical compounds
MXPA05004858A (en) 2002-11-04 2005-07-22 Astrazeneca Ab Quinazoline derivatives as src tyrosine kinase inhibitors.
DK1625121T3 (en) 2002-12-20 2010-05-10 Pfizer Prod Inc Pyrimidine derivatives in the treatment of abnormal cell growth
WO2004058781A1 (en) 2002-12-24 2004-07-15 Astrazeneca Ab Phosphonooxy quinazoline derivatives and their pharmaceutical use
GB0309850D0 (en) * 2003-04-30 2003-06-04 Astrazeneca Ab Quinazoline derivatives
WO2004106308A1 (en) * 2003-05-27 2004-12-09 Pfizer Products Inc. Quinazolines and pyrido [3,4-d] pyrimidines as receptor tyrosine kinase inhibitors
PA8603801A1 (en) * 2003-05-27 2004-12-16 Janssen Pharmaceutica Nv Quinazoline derivatives
TW200510373A (en) 2003-07-14 2005-03-16 Neurogen Corp Substituted quinolin-4-ylamine analogues
US7329664B2 (en) 2003-07-16 2008-02-12 Neurogen Corporation Substituted (7-pyridyl-4-phenylamino-quinazolin-2-yl)-methanol analogues
CA2535614C (en) 2003-08-14 2009-12-22 Array Biopharma Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
US7501427B2 (en) 2003-08-14 2009-03-10 Array Biopharma, Inc. Quinazoline analogs as receptor tyrosine kinase inhibitors
JP4795952B2 (en) 2003-09-16 2011-10-19 アストラゼネカ アクチボラグ Quinazoline derivatives as tyrosine kinase inhibitors
GB0322409D0 (en) 2003-09-25 2003-10-29 Astrazeneca Ab Quinazoline derivatives
EP1669348A4 (en) 2003-09-30 2009-03-11 Eisai R&D Man Co Ltd Novel antifungal agent comprising heterocyclic compound
US7223761B2 (en) 2003-10-03 2007-05-29 Amgen Inc. Salts and polymorphs of a potent antidiabetic compound
EP1678166B1 (en) 2003-10-14 2009-07-29 The Arizona Board of Regents on Behalf of the University of Arizona Protein kinase inhibitors
US20090099165A1 (en) 2003-10-14 2009-04-16 Arizona Board Of Regents On Behalf Of The University Of Arizona Protein Kinase Inhibitors
US7488823B2 (en) 2003-11-10 2009-02-10 Array Biopharma, Inc. Cyanoguanidines and cyanoamidines as ErbB2 and EGFR inhibitors
US7683172B2 (en) 2003-11-11 2010-03-23 Eisai R&D Management Co., Ltd. Urea derivative and process for preparing the same
US20050267182A1 (en) 2003-11-13 2005-12-01 Ambit Biosciences Corporation Urea derivatives as FLT-3 modulators
GB0326459D0 (en) 2003-11-13 2003-12-17 Astrazeneca Ab Quinazoline derivatives
AU2004298448B2 (en) 2003-12-18 2010-09-09 Janssen Pharmaceutica N.V. Pyrido- and pyrimidopyrimidine derivatives as anti- proliferative agents
AU2004309166B2 (en) 2003-12-23 2008-02-21 Pfizer Inc. Novel quinoline derivatives
ES2315834T3 (en) 2004-02-03 2009-04-01 Astrazeneca Ab Quinazoline derivatives.
TW200529846A (en) 2004-02-20 2005-09-16 Wyeth Corp 3-quinolinecarbonitrile protein kinase inhibitors
US20070208023A1 (en) * 2004-04-16 2007-09-06 Smithkline Beecham Corporation Cancer Treatment Method
KR20070011501A (en) * 2004-04-28 2007-01-24 애로우 쎄라퓨틱스 리미티드 Morpholinylanilinoquinazoline derivatives for use as antiviral agents
AP2204A (en) 2004-05-06 2011-02-07 Warner Lambert Co 4-phenylamino-quinazolin-6-yl-amides.
JP2008501675A (en) * 2004-06-04 2008-01-24 アストラゼネカ アクチボラグ Quinazoline derivatives as Erbb receptor tyrosine kinase
AT428421T (en) 2004-09-17 2009-05-15 Eisai R&D Man Co Ltd A medicinal composition with improved stability and reduced gelling
TW200621251A (en) 2004-10-12 2006-07-01 Neurogen Corp Substituted biaryl quinolin-4-ylamine analogues
AU2005293336B2 (en) 2004-10-12 2009-05-28 Astrazeneca Ab Quinazoline derivatives
EP1655295A1 (en) 2004-11-03 2006-05-10 Schering Aktiengesellschaft Anthranilamide pyridinureas as VEGF receptor kinase inhibitors
US7906533B2 (en) 2004-11-03 2011-03-15 Bayer Schering Pharma Ag Nicotinamide pyridinureas as vascular endothelial growth factor (VEGF) receptor kinase inhibitors
EP1657241A1 (en) 2004-11-03 2006-05-17 Schering Aktiengesellschaft Novel anthranilamide pyridinureas as VEGF receptor kinase inhibitors
IL183705A (en) 2004-12-08 2012-02-29 Janssen Pharmaceutica Nv Macrocyclic quinazole derivatives and their use as mtki
JP4881875B2 (en) 2004-12-14 2012-02-22 アストラゼネカ アクチボラグ Pyrazolopyrimidine compounds as antitumor agents
EP1833482A4 (en) 2005-01-03 2011-02-16 Myriad Genetics Inc Compounds and therapeutical use thereof
AT521603T (en) 2005-02-26 2011-09-15 Astrazeneca Ab Quinazoline derivatives as tyrosine kinase inhibitors
ES2351613T3 (en) * 2005-03-03 2011-02-08 Santen Pharmaceutical Co., Ltd. New cyclic compound having a group quinolylalkylthio.
JP4874958B2 (en) 2005-03-30 2012-02-15 エーザイ・アール・アンド・ディー・マネジメント株式会社 Antifungal agents containing pyridine derivatives
US7825244B2 (en) 2005-06-10 2010-11-02 Janssen Pharmaceutica Nv Intermediates useful in the synthesis of alkylquinoline and alkylquinazoline kinase modulators, and related methods of synthesis
US8071768B2 (en) 2005-06-10 2011-12-06 Janssen Pharmaceutica, N.V. Alkylquinoline and alkylquinazoline kinase modulators
EP1910296B1 (en) 2005-07-27 2010-04-21 F.Hoffmann-La Roche Ag 4-aryloxy quinoline derivatives as 5-ht6 modulators
JP4989476B2 (en) 2005-08-02 2012-08-01 エーザイ・アール・アンド・ディー・マネジメント株式会社 Methods for assaying the effects of angiogenesis inhibitors
ES2354457T3 (en) 2005-09-20 2011-03-15 Astrazeneca Ab Compounds of 4- (1H-indazol-5-ylamino) quinazoline as inhibitors of erbB receptor tyrosine kinase for treating cancer.
GB0520475D0 (en) * 2005-10-07 2005-11-16 Arrow Therapeutics Ltd Chemical compounds
TWI385169B (en) 2005-10-31 2013-02-11 Eisai R&D Man Co Ltd Heterocyclic substituted pyridine derivatives and antifungal agent containing same
KR101086967B1 (en) 2005-11-15 2011-11-29 어레이 바이오파마 인크. N4-phenyl-quinazoline-4-amine derivatives and related compounds as erbb type i receptor tyrosine kinase inhibitors for the treatment of hyperproliferative diseases
US7960545B2 (en) 2005-11-23 2011-06-14 Natco Pharma Limited Process for the prepartion of erlotinib
EP1971611B1 (en) 2005-12-21 2012-10-10 Abbott Laboratories Anti-viral compounds
CN102702194A (en) 2005-12-21 2012-10-03 雅培制药有限公司 Anti-viral compounds
CN102702193A (en) 2005-12-21 2012-10-03 雅培制药有限公司 Anti-viral compounds
CN101003514A (en) 2006-01-20 2007-07-25 上海艾力斯医药科技有限公司 Derivative of quinazoline, preparation method and usage
UY30183A1 (en) 2006-03-02 2007-10-31 Astrazeneca Ab Quinoline derivatives
WO2007119361A1 (en) 2006-03-17 2007-10-25 Mitsubishi Gas Chemical Company, Inc. Method for production of quinazolin-4-on derivative
EP2021338A1 (en) 2006-05-09 2009-02-11 Pfizer Products Inc. Cycloalkylamino acid derivatives and pharmaceutical compositions thereof
CN101443009A (en) 2006-05-18 2009-05-27 卫材R&D管理有限公司 Antitumor agent for thyroid cancer
CN101490060B (en) 2006-07-13 2012-04-11 詹森药业有限公司 Quinazoline derivatives Mtki
CN101511793B (en) 2006-08-28 2011-08-03 卫材R&D管理有限公司 Antitumor agent for undifferentiated gastric cancer
EP2065377B1 (en) 2006-09-21 2011-11-23 Eisai R&D Management Co., Ltd. Pyridine derivative substituted by heteroaryl ring, and antifungal agent comprising the same
US8754107B2 (en) 2006-11-17 2014-06-17 Abbvie Inc. Aminopyrrolidines as chemokine receptor antagonists
EP2094276A4 (en) 2006-12-20 2011-01-05 Abbott Lab Anti-viral compounds
KR101445892B1 (en) 2007-01-29 2014-09-29 에자이 알앤드디 매니지먼트 가부시키가이샤 Composition for treatment of undifferentiated-type of gastric cancer
CN101245050A (en) * 2007-02-14 2008-08-20 上海艾力斯医药科技有限公司 4-aniline quinazoline derivative salt
BRPI0810411B1 (en) 2007-04-18 2019-09-10 Pfizer Prod Inc sulfonyl amide derivatives for the treatment of abnormal cell growth, its sos as well as pharmaceutical composition
AU2008246798A1 (en) 2007-04-27 2008-11-13 Eisai R&D Management Co., Ltd. Salt of heterocycle-substituted pyridine derivative or crystal thereof
JP5460589B2 (en) * 2007-07-13 2014-04-02 アイカジェン, インコーポレイテッド Sodium channel inhibitor
AU2008281849B2 (en) 2007-07-27 2013-11-28 Janssen Pharmaceutica Nv Pyrrolopyrimidines
UA101168C2 (en) 2007-10-29 2013-03-11 Натко Фарма Лимитед Novel 4-(tetrazol-5-yl)-quinazoline derivatives as anti cancer agents
WO2009058937A2 (en) * 2007-11-01 2009-05-07 Wyeth Heteroaryl ethers and processes for their preparation
CA2704000C (en) 2007-11-09 2016-12-13 Eisai R&D Management Co., Ltd. Combination of anti-angiogenic substance and anti-tumor platinum complex
CA2710039C (en) 2007-12-26 2018-07-03 Critical Outcome Technologies, Inc. Semicarbazones, thiosemicarbazones and related compounds and methods for treatment of cancer
US8513287B2 (en) 2007-12-27 2013-08-20 Eisai R&D Management Co., Ltd. Heterocyclic ring and phosphonoxymethyl group substituted pyridine derivatives and antifungal agent containing same
MX2010008621A (en) 2008-02-07 2010-09-24 Boehringer Ingelheim Int Spirocyclic heterocycles, medicaments containing said compounds, use thereof and method for their production.
CA2718538A1 (en) * 2008-04-16 2009-10-22 Max-Planck-Gesellschaft Zur Forderung Der Wissenschaften E.V. Quinoline derivatives as axl kinase inhibitors
WO2009137714A2 (en) 2008-05-07 2009-11-12 Teva Pharmaceutical Industries Ltd. Forms of lapatinib ditosylate and processes for preparation thereof
US8088782B2 (en) 2008-05-13 2012-01-03 Astrazeneca Ab Crystalline 4-(3-chloro-2-fluoroanilino)-7 methoxy-6-{[1-(N-methylcarbamoylmethyl)piperidin-4-yl]oxy}quinazoline difumarate form A
US8426430B2 (en) * 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
JP2010018531A (en) * 2008-07-09 2010-01-28 Sumitomo Seika Chem Co Ltd Method for producing 3-benzyloxybenzenethiol
WO2010006438A1 (en) 2008-07-17 2010-01-21 Critical Outcome Technologies Inc. Thiosemicarbazone inhibitor compounds and cancer treatment methods
EP2313397B1 (en) 2008-08-08 2016-04-20 Boehringer Ingelheim International GmbH Cyclohexyloxy substituted heterocycles, medicine containing these connections, their application and production method
EP2241565A1 (en) 2009-01-15 2010-10-20 Universität Leipzig Aurora kinase inhibitors compounds
NZ618004A (en) 2009-01-16 2015-06-26 Exelixis Inc Malate salt of n-(4-{ [6,7-bis(methyloxy)quinolin-4-yl]oxy} phenyl)-n’-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide, and crystalline forms thereof for the treatment of cancer
KR101106050B1 (en) 2009-03-25 2012-01-18 한국과학기술연구원 Aminoquinoline derivatives, preparation method thereof and pharmaceutical composition comprising the same
EP2473500A2 (en) 2009-09-01 2012-07-11 Pfizer Inc. Benzimidazole derivatives
NZ598516A (en) 2009-09-03 2013-02-22 Squibb Bristol Myers Co Quinazolines as potassium ion channel inhibitors
CA2794952C (en) 2010-04-01 2018-05-15 Critical Outcome Technologies Inc. Compounds and method for treatment of hiv
WO2011140442A1 (en) * 2010-05-07 2011-11-10 Glaxo Group Limited Amino-quinolines as kinase inhibitors
EP2586443B1 (en) 2010-06-25 2016-03-16 Eisai R&D Management Co., Ltd. Antitumor agent using compounds having kinase inhibitory effect in combination
US9056865B2 (en) 2010-10-20 2015-06-16 Pfizer Inc. Pyridine-2-derivatives as smoothened receptor modulators
CN103857288B (en) 2011-03-04 2016-09-21 葛兰素史密斯克莱知识产权发展有限公司 Amino group as kinase inhibitors - quinoline
CA2828946C (en) 2011-04-18 2016-06-21 Eisai R&D Management Co., Ltd. Therapeutic agent for tumor
ES2705950T3 (en) 2011-06-03 2019-03-27 Eisai R&D Man Co Ltd Biomarkers to predict and assess the responsiveness of subjects with thyroid and kidney cancer to lenvatinib compounds
CN102850280B (en) * 2011-06-30 2015-06-10 陕西师范大学 6,7-dialkyloxy-4-substituted phenylamino quinazoline compounds and preparation methods
WO2013013614A1 (en) * 2011-07-28 2013-01-31 南京英派药业有限公司 4-(3-heteroarylarylamino)quinazoline and 1-(3-heteroarylarylamino)isoquinoline as hedgehog pathway inhibitor and use thereof
TWI547494B (en) 2011-08-18 2016-09-01 Glaxosmithkline Ip Dev Ltd As the amine quinazoline kinase inhibitors of
EP2758402B9 (en) 2011-09-22 2016-09-14 Pfizer Inc Pyrrolopyrimidine and purine derivatives
TW201425307A (en) 2012-09-13 2014-07-01 Glaxosmithkline Llc Amino-quinolines as kinase inhibitors
AR092529A1 (en) 2012-09-13 2015-04-22 Glaxosmithkline Llc Aminoquinazoline compound, pharmaceutical composition comprising the same and use of said compound for the preparation of a medicament
CN104755463A (en) 2012-12-21 2015-07-01 卫材R&D管理有限公司 Amorphous form of quinoline derivative, and method for producing same
CN108250142A (en) * 2013-02-01 2018-07-06 维尔斯达医疗公司 Amine compounds having anti-inflammatory, antifungal, antiparasitic and anticancer activity
AR094707A1 (en) 2013-02-21 2015-08-19 Glaxosmithkline Ip Dev Ltd Compound quinazolin-4-amine, pharmaceutical composition comprising it and its use for the treatment of a disease mediated by kinase rip2
RU2682332C2 (en) 2013-09-16 2019-03-19 Астразенека Аб Therapeutic polymeric nanoparticles and methods of making and using same
CN105916853B (en) 2013-11-21 2018-07-27 辉瑞公司 2,6- substituted purin derivatives and its purposes in treating proliferative diseases
WO2015155624A1 (en) 2014-04-10 2015-10-15 Pfizer Inc. Dihydropyrrolopyrimidine derivatives
KR20160149256A (en) 2014-04-30 2016-12-27 화이자 인코포레이티드 Cycloalkyl-linked diheterocycle derivatives
WO2016001789A1 (en) 2014-06-30 2016-01-07 Pfizer Inc. Pyrimidine derivatives as pi3k inhibitors for use in the treatment of cancer
CA2957005A1 (en) 2014-08-28 2016-03-03 Eisai R&D Management Co., Ltd. High-purity quinoline derivative and method for manufacturing same
EP3283466A4 (en) * 2015-04-16 2018-09-12 Icahn School of Medicine at Mount Sinai Ksr antagonists
WO2017009751A1 (en) 2015-07-15 2017-01-19 Pfizer Inc. Pyrimidine derivatives
CN105384699B (en) 2015-10-23 2016-10-12 中国人民解放军南京军区南京总医院 A novel quinazoline derivative and a preparation method and application lu1501
CN105503747B (en) * 2015-12-03 2017-12-19 中国人民解放军南京军区南京总医院 One kind of quinazoline derivatives and their preparation method and application lu1507
CN105669567A (en) * 2015-12-28 2016-06-15 上海应用技术学院 Tyrosine kinase inhibitor, preparation method and application thereof
TW201904960A (en) 2017-04-27 2019-02-01 瑞典商阿斯特捷利康公司 C5- anilino quinazoline compounds and their use in the treatment of cancer
CN108373452A (en) * 2018-02-09 2018-08-07 安庆奇创药业有限公司 A kind of preparation method of lapatinib key intermediate

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2474823A (en) * 1945-11-05 1949-07-05 Parke Davis & Co Quinoline compounds and process of making same
PH22302A (en) * 1985-02-11 1988-07-22 Fujisawa Pharmaceutical Co Piperidine compounds
WO1986006718A1 (en) * 1985-05-17 1986-11-20 The Australian National University Antimalarial compounds
IL89028D0 (en) * 1988-01-29 1989-08-15 Lilly Co Eli Quinoline,quinazoline and cinnoline derivatives
IL89027A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Quinazoline derivatives, process for their preparation and fungicidal, insecticidal and miticidal compositions containing them
IL89029A (en) * 1988-01-29 1993-01-31 Lilly Co Eli Fungicidal quinoline and cinnoline derivatives, compositions containing them, and fungicidal methods of using them
US5141941A (en) * 1988-11-21 1992-08-25 Ube Industries, Ltd. Aralkylamine derivatives, and fungicides containing the same
US5710158A (en) * 1991-05-10 1998-01-20 Rhone-Poulenc Rorer Pharmaceuticals Inc. Aryl and heteroaryl quinazoline compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
WO1993003030A1 (en) * 1991-08-02 1993-02-18 Pfizer Inc. Quinoline derivatives as immunostimulants

Also Published As

Publication number Publication date
TR199501137A2 (en) 1996-06-21
IL115341D0 (en) 1995-12-31
JPH10505600A (en) 1998-06-02
AU3482495A (en) 1996-04-09
EP0782570A1 (en) 1997-07-09
WO1996009294A1 (en) 1996-03-28

Similar Documents

Publication Publication Date Title
DE69528655D1 (en) Asymmetrische femorale prothese
DE69531947D1 (en) Ausbreitbare ringprothese
DE69530493D1 (en) Ablationsgerät
GB2294043B (en) Bisresorcinyltriazines
DE69524254D1 (en) Nadelmagazin
DE69502378D1 (en) Metalloproteinaseinhibitoren
DE69529412D1 (en) Hydromorphone-therapie
DE69512891D1 (en) Metalloproteinaseinhibitoren
DE69532245D1 (en) Imidazolderivat
DE59508177D1 (en) Modulare hüftgelenkprothese
DE69512030D1 (en) Cerebral-dilator
DE69528457D1 (en) Modulares blockwand-haltesystem
GB2293823B (en) 2-Hydroxyphenyltriazines
DE69522947D1 (en) Phenylxanthin-derivate
DE69534962D1 (en) Htk-ligand
DE69531859D1 (en) Bioumbaubare collagentransplantat prothese
DE69523560D1 (en) Fluorinzelle
DE69534778D1 (en) Cathepsin-02-protease
DE69533314D1 (en) Polyester-isolation
DE69526822D1 (en) Xanthin-derivate
DE69506554D1 (en) Schrumpfbares originalitätsband
GR3031464T3 (en) Polyolpolyhydroxystearates
EP0696731A3 (en) Cytoanalyzer
HRP950428A2 (en) Benzoxazolyl- and benzo-thiazolyl-oxazolidinones
HU9500396D0 (en) 4-amino-1-piperidyl-benzoyl-guanidine